Speakers
Prof. Stefan ANKER
Professor of (Tissue) Homeostasis in Cardiology & Metabolism, Department of Cardiology, Charité Campus Virchow-Klinikum, Germany
Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor of Cardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014-17).
Dr. Anker has authored more than 800 original papers, reviews, and editorials that are well cited (total citations: >66,000, h-index: 115, papers with ≥ 200 citations: 80; source: Scopus, 20th Jan, 2019).
For his work Dr. Anker has won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. He obtained a number of fellowships & grants, incl. 2 from NIH (WARCEF EU), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for “SICA-HF” (EU-FP7). He received grants for three IITs that are currently running for >15 Mill EUR (from DZHK Germany & several industries).
Dr. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board 2012-2018. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14). He is founding Editor-in-Chief of the open access journal ESC Heart Failure. Dr. Anker worked in several ESC Guideline task forces (e.g. the ESC HF guidelines 2012 & 2016).
Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders since 2008 (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle since 2010 (JCSM, 2017-IF: 12.51, see www.jcsm.info).
Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, EMPEROR-HFpEF, Fair-HFpEF, EMPERIAL-HFpEF, RELIEVE-HF, REVIVE-HF) as well as in the past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, IMPULSE-HF & BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).